Gene therapy has become a one-time treatment method for a complete cure by fixing genomic errors which altered the protein functions of normal cells. The high titer virus packaging and purity are essential for the success of clinical gene therapy. In this presentation, Dr. Rejean Wang, reports on establishing a facility to manufacture GLP-grade viruses and to develop the relevant QC assays at Frontage. Our efforts will facilitate the application of this modern cutting-edge technology in the clinical arena.

Hosted by ISSX, Frontage's own Dr John Kapeghian discusses the "Cost Effective and Efficient Progression of Lead Drug Candidates to First in Human Studies in the Two Largest Economies in the World: USA and China."

This study is aimed at developing a Nanoemulsion formulation of a poorly water-soluble and thermally, oxidatively, and photolytically unstable active pharmaceutical ingredient (API) for ophthalmic application, specifically for the reduction of intraocular pressure (IOP) and to provide neuroprotection.